Mfon E Umoh1, Christina Fournier1, Yingjie Li1, Meraida Polak1, Latoya Shaw1, John E Landers1, William Hu1, Marla Gearing1, Jonathan D Glass2. 1. From the Center for Neurodegenerative Disease (M.E.U., W.H., M.G., J.D.G.), Department of Neurology (M.E.U., C.F., Y.L., M.P., L.S., W.H., M.G., J.D.G.), and Pathology and Laboratory Medicine (M.G., J.D.G.), Emory University School of Medicine, Atlanta, GA; and the Department of Neurology (J.E.L.), University of Massachusetts Medical School, Worcester. 2. From the Center for Neurodegenerative Disease (M.E.U., W.H., M.G., J.D.G.), Department of Neurology (M.E.U., C.F., Y.L., M.P., L.S., W.H., M.G., J.D.G.), and Pathology and Laboratory Medicine (M.G., J.D.G.), Emory University School of Medicine, Atlanta, GA; and the Department of Neurology (J.E.L.), University of Massachusetts Medical School, Worcester. Jglas03@emory.edu.
Abstract
OBJECTIVE: We investigated whether the C9orf72 expansion mutation in patients with amyotrophic lateral sclerosis (ALS) is associated with unique demographic and clinical features. METHODS: Between 2001 and 2015, approximately half of all patients attending the Emory ALS Clinic agreed to donate DNA for research. This research cohort of 781 patients was screened for the C9orf72 expansion, and demographic and clinical data were compared between those with and without the C9orf72 mutation. For mutation carriers without a family history of ALS, we sought further family history of dementia and other non-ALS neurodegenerative diseases in first-degree relatives. RESULTS: The C9orf72 expansion was identified in 61 patients (7.8%). Compared to those without the expansion mutation, these patients did not differ in race, age, or site of onset. As expected, C9orf72 patients were more likely to have a family history of ALS (59% vs 7.9%) and to present with comorbid frontotemporal dementia (FTD) (14.8% vs 1.7%). Survival was shorter in patients with the expansion (log-rank χ(2)[1] = 45.323, p < 0.001). Further investigation in 28 patients initially categorized as having no known family history of ALS identified a family history of dementia in 16 cases; 6 of these had characteristics suggestive of FTD. CONCLUSIONS: Comparing the C9orf72 ALS population to the general ALS population, there were no differences in race, age at onset, or proportion of patients with bulbar onset disease. Differences identified in patients with the C9orf72 mutation included shortened survival and an equal proportion of men and women. In addition, we found that assessing family history for dementia may identify other family members likely to be carrying the C9orf72 expansion, reduce the number of sporadic cases, and thus increase our understanding of disease penetrance.
OBJECTIVE: We investigated whether the C9orf72 expansion mutation in patients with amyotrophic lateral sclerosis (ALS) is associated with unique demographic and clinical features. METHODS: Between 2001 and 2015, approximately half of all patients attending the Emory ALS Clinic agreed to donate DNA for research. This research cohort of 781 patients was screened for the C9orf72 expansion, and demographic and clinical data were compared between those with and without the C9orf72 mutation. For mutation carriers without a family history of ALS, we sought further family history of dementia and other non-ALS neurodegenerative diseases in first-degree relatives. RESULTS: The C9orf72 expansion was identified in 61 patients (7.8%). Compared to those without the expansion mutation, these patients did not differ in race, age, or site of onset. As expected, C9orf72patients were more likely to have a family history of ALS (59% vs 7.9%) and to present with comorbid frontotemporal dementia (FTD) (14.8% vs 1.7%). Survival was shorter in patients with the expansion (log-rank χ(2)[1] = 45.323, p < 0.001). Further investigation in 28 patients initially categorized as having no known family history of ALS identified a family history of dementia in 16 cases; 6 of these had characteristics suggestive of FTD. CONCLUSIONS: Comparing the C9orf72ALS population to the general ALS population, there were no differences in race, age at onset, or proportion of patients with bulbar onset disease. Differences identified in patients with the C9orf72 mutation included shortened survival and an equal proportion of men and women. In addition, we found that assessing family history for dementia may identify other family members likely to be carrying the C9orf72 expansion, reduce the number of sporadic cases, and thus increase our understanding of disease penetrance.
Authors: Mariely DeJesus-Hernandez; Ian R Mackenzie; Bradley F Boeve; Adam L Boxer; Matt Baker; Nicola J Rutherford; Alexandra M Nicholson; NiCole A Finch; Heather Flynn; Jennifer Adamson; Naomi Kouri; Aleksandra Wojtas; Pheth Sengdy; Ging-Yuek R Hsiung; Anna Karydas; William W Seeley; Keith A Josephs; Giovanni Coppola; Daniel H Geschwind; Zbigniew K Wszolek; Howard Feldman; David S Knopman; Ronald C Petersen; Bruce L Miller; Dennis W Dickson; Kevin B Boylan; Neill R Graff-Radford; Rosa Rademakers Journal: Neuron Date: 2011-09-21 Impact factor: 17.173
Authors: Giuseppe Borghero; Maura Pugliatti; Francesco Marrosu; Maria Giovanna Marrosu; Maria Rita Murru; Gianluca Floris; Antonino Cannas; Leslie D Parish; Patrizia Occhineri; Tea B Cau; Daniela Loi; Anna Ticca; Sebastiano Traccis; Umberto Manera; Antonio Canosa; Cristina Moglia; Andrea Calvo; Marco Barberis; Maura Brunetti; Hannah A Pliner; Alan E Renton; Mike A Nalls; Bryan J Traynor; Gabriella Restagno; Adriano Chiò Journal: Neurobiol Aging Date: 2014-07-18 Impact factor: 4.673
Authors: Francesca L Conforti; Rita Barone; Salvatore Lo Fermo; Claudia Giliberto; Francesco Patti; Antonio Gambardella; Aldo Quattrone; Mario Zappia Journal: Amyotroph Lateral Scler Date: 2011-05
Authors: Bradley F Boeve; Kevin B Boylan; Neill R Graff-Radford; Mariely DeJesus-Hernandez; David S Knopman; Otto Pedraza; Prashanthi Vemuri; David Jones; Val Lowe; Melissa E Murray; Dennis W Dickson; Keith A Josephs; Beth K Rush; Mary M Machulda; Julie A Fields; Tanis J Ferman; Matthew Baker; Nicola J Rutherford; Jennifer Adamson; Zbigniew K Wszolek; Anahita Adeli; Rodolfo Savica; Brendon Boot; Karen M Kuntz; Ralitza Gavrilova; Andrew Reeves; Jennifer Whitwell; Kejal Kantarci; Clifford R Jack; Joseph E Parisi; John A Lucas; Ronald C Petersen; Rosa Rademakers Journal: Brain Date: 2012-03 Impact factor: 13.501
Authors: Mary K Floeter; Bryan J Traynor; Jennifer Farren; Laura E Braun; Michael Tierney; Edythe A Wiggs; Tianxia Wu Journal: Neurology Date: 2017-06-14 Impact factor: 9.910
Authors: Tania F Gendron; Lillian M Daughrity; Michael G Heckman; Nancy N Diehl; Joanne Wuu; Timothy M Miller; Pau Pastor; John Q Trojanowski; Murray Grossman; James D Berry; William T Hu; Antonia Ratti; Michael Benatar; Vincenzo Silani; Jonathan D Glass; Mary Kay Floeter; Andreas Jeromin; Kevin B Boylan; Leonard Petrucelli Journal: Ann Neurol Date: 2017-07 Impact factor: 10.422
Authors: Hyerim Kim; Junghwa Lim; Han Bao; Bin Jiao; Se Min Canon; Michael P Epstein; Keqin Xu; Jie Jiang; Janani Parameswaran; Yingjie Li; Kenneth H Moberg; John E Landers; Christina Fournier; Emily G Allen; Jonathan D Glass; Thomas S Wingo; Peng Jin Journal: Hum Mol Genet Date: 2019-07-15 Impact factor: 6.150